Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease

BACKGROUND: Vedolizumab, an α4β7 integrin antagonist, is an effective therapy for Crohn’s disease (CD). Biomarkers are needed to guide therapy and predict outcomes. This study evaluated biomarker concentrations and outcomes in patients with CD undergoing vedolizumab treatment. METHODS: Sera at weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmer, Ariela K., Battat, Robert, Dulai, Parambir S., Vande Casteele, Niels, Nguyen, Nghia, Jain, Anjali, Miralles, Ara, Neill, Jennifer, Le, Helen, Singh, Siddharth, Rivera-Nieves, Jesus, Sandborn, William J., Boland, Brigid S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675888/
https://www.ncbi.nlm.nih.gov/pubmed/33240396
http://dx.doi.org/10.1177/1756284820971214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675888/
https://www.ncbi.nlm.nih.gov/pubmed/33240396
http://dx.doi.org/10.1177/1756284820971214

Ejemplares similares